JPRN-jRCT2033230513招募中2 期
ong-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells
Hayakawa Jin0 个研究点目标入组 77 人开始时间: 2023年12月15日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored study, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
- •2. Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.
排除标准
- •Not Applicable
研究者
相似试验
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.EUCTR2017-001465-24-NLCelgene Corporation218
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-NOCelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-DECelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.Defined by parent protocol. The study will enroll all adult and paediatric subjects who received at least one genetically modified T cells infusion in a previous Celgene sponsored study.MedDRA version: 21.0Level: LLTClassification code 10025631Term: Malignant lymphoid neoplasm NOSSystem Organ Class: 100000004864EUCTR2017-001465-24-BECelgene Corporation525
进行中（未招募）
1 期
ong-Term Follow-up Protocol for Subjects Treated with JCAR015B-cell Acute Lymphoblastic Leukemia (ALL)MedDRA version: 19.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864EUCTR2016-003400-31-BECelgene Corporation105